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The relationship between miRNA expression and the onset, development, and 
advancement of aggressive cancers keeps miRNAs a subject of keen interest, and is the primary 
focus of this study.  miRNAs are known to play critical roles as both proto-oncogene and tumor 
suppressor gene products.  We are hypothesizing that stresses imposed within the tumor 
microenvironment of a cancer cell may become overly harsh, creating unsuitable conditions and 
provoking a cellular response that impacts expression levels for select miRNAs, and ultimately, 
the cancer cell’s invasiveness.  In this study, we explore how stresses affect levels of expression 
for miR-145 and miR-330-3p in MCF7, MB-468, and MB-231 breast cancer cell lines, and we 
examine the effects of these altered miRNA expression levels on the invasiveness of MCF7 and 
MB468 cells. 
miR-145 is a tumor suppressor found to be down regulated in breast cancers.  Its 
regulatory actions and targets can be associated with a number of critical cellular pathways.  In 
contrast, miRNA-330-3p is a protooncogene product found to be overexpressed in breast 
cancers.  We expected to find lowered levels of miR-145 expression and increased levels of miR-
330-3p expression in breast cancer cells exposed to stress, compared with breast cancer cells 
grown in normal conditions.  We also expected MCF7 and MB468 cells exposed to stress would 
prove to be more invasive than those grown in normal conditions. 
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Although mixed results are reported, some data collected for this study appear to support 
our hypothesis.  miRNA expression data in agreement with this hypothesis include down-
regulation of miR-145 in cells exposed to dual stress conditions, as well as upregulation of miR-
330-3p in cells exposed to hypoxic stress (for all 3 cell lines), and in MCF7 and MB231 cells 
exposed to heat stress.  Some invasion data in agreement with our hypothesis are also reported.  
Cell migration increased among MCF7 cells exposed to hypoxic stress, and a marked increase in 
cell migration was observed for MB468 cells under all stress conditions, compared with those 
under normal conditions.  These data are all in agreement with our hypothesis, suggesting that 
stress conditions in the tumor microenvironment could be a trigger for metastatic cell behavior.    
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Cancer describes a complex collection of diseases that continue to threaten the lives of 
individuals across all demographics of society.  The National Cancer Institute (NCI) has 
estimated that 1,806,950 new cases of cancer will be diagnosed in the US in 2020; projections 
have also been published for cases of all cancers that will end in death, and these numbers are 
reported at 606,520 (1).  Sobering projections have also been broken down and established for 
specific types of cancers: breast cancers remain an imposing threat to women across the globe, 
and in the United States estimates published by the NCI for this year reflect newly diagnosed 
cases will number at 276,480, and 42,170 cases of breast cancers will result in death (1). 
Characteristics common to all cancers include genetic abnormalities that interfere with 
standard restraints imposed on cell cycle progression, ultimately resulting in unchecked cell 
proliferation, and in the case of metastatic disease, the ability of cancerous cells to migrate to 
other sites in the body and establish tumors in new locations.  These genetic deviations affect 
two large categories of genes: proto-oncogenes and tumor suppressor genes.  Proto-oncogenes 
encompass genes whose products are associated with cell cycle progression and are important 
elements of cell signaling pathways, as well as those connected with cell survival. Tumor 
suppressor genes include those whose products forestall progression through the cell cycle, as 
well as those implicated in preserving genomic integrity. 
Cancerous tumors may contain an expansive array of disparate mutations affecting genes 
from both of these categories; these mutations can alter the normal expression of the genes and 
the normal function of the gene products.  This type of gene dysregulation, exacerbated by the 
faulty DNA repair pathways usually seen in cancer cells, has been shown to play a prominent 
role in the development and spread of cancers, as well as to create daunting challenges for 
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treatment.  Genetic perturbations seen in cancer include point mutations, translocations, 
amplifications, and deletions. Point mutations are single base pair changes that can be either 
transitions or transversions; a transition involves the replacement of a purine with another purine 
(for example, changing an A to G) or a pyrimidine with another pyrimidine (for example, 
changing a T to C), while transversions occur when a purine is changed to a pyrimidine or vice 
versa.  These mutations may have substantial impacts, depending on where the point mutation 
occurs.  Translocations take place due to breaks in the sugar phosphate backbone; a section of 
one chromosome is broken off or separated, and then attached to another.  Translocations can be 
very important to the development of cancers; they may affect standard regulation of gene 
expression or change protein structure and function, depending on where they occur.  
 Amplifications are known to generate many copies of the same gene, resulting in 
overexpression, and are also seen in many cancers.  Point mutations, translocations, and 
amplifications are known to affect expression of protooncogenes, or the function of their 
products.  Deletions are mutations that involve the removal of large sections of DNA that may 
affect several different genes; these mutations often affect tumor suppressor genes or their 
products and are often associated with contributing to a loss of heterozygosity, or LOH, which is 
often a key step in the development of cancer.   
Mutations that spur deviant expression or improperly initiate action of proto-oncogene 
products may drive a cell to become cancerous; these are usually dominant and are referred to as 
‘gain of function’ mutations.  Additionally, those that negate expression of tumor suppressor 
genes or disengage the actions of their products may also drive a cell to become cancerous; these 
are normally recessive and are known as ‘loss of function’ mutations.  Other factors that can 
predispose cells to becoming cancerous include epigenetic silencing, various exposures 
8 
 
encountered within an individual’s environment (which can contribute to both mutations and 
altered epigenetic silencing), as well as exposure to certain viruses.  
As mentioned above, proto-oncogene products are often involved in signaling pathways 
that mediate cell proliferation.  Mutations that affect elements of these various cell signaling 
pathways may lead to uncontrolled cell proliferation and thus can have a dramatic, wide-ranging 
impact in cancers.  At least four major signaling pathways are involved in controlling cell 
proliferation:  the RAS MAP Kinase pathway, Wnt signaling pathways, Hedgehog signaling, and 
Notch signaling.  I will briefly discuss each of these pathways.   
The Ras MAP Kinase Pathway  
The Ras MAP Kinase pathway is used by a wide variety of cells to respond to a wide 
variety of signaling molecules.  Key components of this pathway are products of proto-
oncogenes and include cell membrane receptors, the G protein or guanine nucleotide binding 
protein, Ras, a tyrosine kinase named Src,  a serine/threonine kinase called p21 activated kinase 
(PAK), Growth Factor Receptor Binding protein (Grb2), a Guanine Nucleotide Release Factor 
(GNRF), named Sos, and serine/threonine kinases called MAP kinase kinase kinase (RAF), 
MAP kinase kinase (MEK), and MAP kinase (ERK), (2). 
An ordered pattern of events begins with the interaction of an extracellular stimulus, such 
as a growth factor, with a cell membrane receptor, (2).  This typically results in the receptors 
dimerizing and cross-phosphorylating, which prompts binding to the receptors by Grb2, Src, and 
PAK.  Grb2 binds to the receptor through its SH2 domain, often with another protein called 
SHC, before bringing in Sos.  The GNRF, Sos, is then able to initiate activation of Ras, and Ras 
can draw RAF to the plasma membrane, where it is activated through Src and PAK 
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phosphorylation; active RAF then initiates the action of MEK, which initiates the action of ERK, 
through sequential phosphorylation (2). 
ERK then phosphorylates several transcription factors, including Myc, Jun, and Elk-1, 
which activates Jun and Elk-1 (3).  Phosphorylation by ERK allows Myc to assume a more stable 
form, enabling Myc to bring about the transcription of a vast number of genes (3).  After 
activation by ERK, Elk-1 stimulates transcription of the gene encoding Fos; when Fos is 
available to bind with Jun, they form a dimeric transcription factor called AP-1, which then 
activates the expression of key genes whose products are involved in cell cycle progression (2).  
The series of reactions in this signal transduction pathway ultimately leads to the production of 
copious amounts of proteins needed for cell division. 
Various mutations can affect signal transduction pathways, but those occurring at 
significant regulatory points in a pathway produce greater consequences.  A single point 
mutation in the G protein Ras enables constitutive activation of the Ras MAP Kinase pathway by 
curtailing the GTPase action (GTPase hydrolyzes GTP to GDP) that deactivates the Ras protein; 
in this situation, active Ras will continually recruit RAF to the membrane, and initiate the kinase 
cascade without an extracellular stimulus (2).  Additional components of this pathway may be 
similarly affected by acquired point mutations that cause them to remain in a perpetually active 
configuration, including growth factor receptors, kinases, and transcription factors (2).  In one 
such case, growth factor receptors will continually undergo dimerization and 
autophosphorylation, stimulating the kinase cascade.  Transcription factors such as Myc and Jun 
may also be impacted by these types of mutations, remaining active without phosphorylation by 
ERK; Myc could acquire stability without ERK activation (3). 
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Signaling kinases may also be impacted by these mutations, and Dhillon et al. report 
another important example of a cancerous mutation within this pathway occurs with a 
particularly high frequency in the gene that codes for B-RAF, one of three mammalian isoforms 
of RAF (2).  Most often, cancerous mutations in the gene coding for B-RAF, such as the 
mutation V600E, result in the product’s notably increased kinase action, and consequent increase 
in overall efficiency in the activation of ERK; these mutations are reportedly found in thyroid, 
colon, ovarian, and many other different cancers, as well as in 66% of cancerous melanomas (2).   
Wnt Signaling Pathways 
Another signal transduction pathway that can lead to uncontrolled cell proliferation in 
cancers is a Wnt pathway (4).  This pathway involves the protein, B-catenin, a protein also 
known for its role in cell-to-cell adhesion (4).  The Wnt pathway is initiated when an 
extracellular protein belonging to the Wnt family binds to a receptor; Wnt proteins are associated 
with both cell division and differentiation, and this Wnt pathway is known to prompt 
transcription of a number of the same genes as those activated through the RAS MAP kinase 
pathway. 
Receptors for this pathway are called Frizzled, and they are known to form a heterodimer 
with another protein called LDL-receptor-related protein (LRP), before activation of the protein 
Disheveled (Dvl), (4).  Once the action of Dvl is initiated, it inhibits the normal activity of the 
protein, Glycogen Synthase Kinase 3 (GSK-3), (4).  Active GSK-3 usually binds to form a 
complex with Adenomatous polyposis coli (APC), Axin, and various other proteins that 
ultimately work towards proteasome degradation of B-catenin, which binds to APC (4).  This 
most often occurs through phosphorylation of B-catenin by GSK-3 and casein kinase 1 (CK1), 
although phosphorylation independent paths to B-catenin degradation may also take place (4).  
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Conversely, when GSK-3 is rendered inactive through stimulation of the Wnt pathway, B-catenin 
can disassociate from APC (4).  The integrity of the protein B-catenin is preserved and it remains 
stable (4).  In its stable form, B-catenin then penetrates the nucleus (4).  A co-repressor protein 
called Groucho forms a complex with lymphoid-enhancer factor/T cell factor (LEF/TCF) 
transcription factors in the absence of the Wnt protein signal (4).  Following activation of the 
Wnt pathway, B-catenin enters the nucleus and supplants Groucho; the B-catenin/ LEF/TCF 
complex then drives transcription of numerous genes, including those coding for c-Myc, c-Jun, 
matrilysin, CD44, peroxisome proliferator-activated receptor, cyclin D1, urokinase-type 
plasminogen activator receptor, and fra1, among others (4). 
Mutations affecting members of this pathway are known to contribute to cancers and can 
stimulate tumor growth (4).  Particularly impactful are the mutations occurring in genes that code 
for APC or B-catenin that prevent their binding (4).  This creates a scenario where B-catenin is 
freely permitted to enter the nucleus, initiating constitutive transcription of the aforementioned 
genes.   Increased expression of Cyclin D1 and Myc results in excessive cell division (4).  CD44 
(a transmembrane protein identified as an ECM adhesion molecule), is associated with 
metastases and angiogenesis, and is thought to contribute to drug resistance (5).  Urokinase-type 
plasminogen activator receptor, or the receptor for uPA (a serine protease that can be found 
bound to axons of migrating cells) is thought to help with invasion and migration in cancer cells.  
Matrilysin, or matrix metalloprotease 7 (MMP7), is a member of a family of proteolytic enzymes 
that play crucial roles in cancer cell metastases and invasion through their degradation of ECM 
components; MMP7 is also reported to be critically important for the process of angiogenesis 
that takes place within the microenvironment of the original tumor site, as well as at developing 
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secondary sites (6).  CD44, uPA receptor, and matrilysin overexpression are reportedly apt to 
contribute to the growth of existing tumors as well (4). 
Indeed, authors report that cancerous mutations relevant to this Wnt pathway include 
defects in serine, threonine, and certain other proximate amino acid residues required for 
degradation of B-catenin, and these mutations can be seen in a wide variety of cancers (4).  
These cancers include melanomas, gastric and colon cancers, as well as cancers of the liver, 
ovaries, prostate, and pancreas, among others (4).  APC gene mutations that result in altered 
binding sites for B-catenin or Axin render APC unable to exercise its tumor suppressive actions 
(through facilitating destruction of B-catenin), and heightened levels of both B-catenin and 
functional B-catenin/TCF complexes have been found to be present in cancers (4).  These 
findings note a particularly significant rate of occurrence in colorectal cancers (4). 
Hedgehog Signaling  
The Hedgehog signaling pathway is another pathway having significant implications in 
cancers, and bears many similarities to the Wnt pathway; in fact, several integral proteins 
involved with the Wnt pathway also participate in regulatory roles in the Hedgehog pathway, 
such as kinases GSK-3 and CK1.  Hedgehog proteins (Sonic, or Shh, Indian, or Ihh, and Desert, 
or Dhh), are morphogens playing critical roles in developmental processes and known to be 
associated with embryogenesis; Hedgehog signaling is implicated in the proliferation of various 
tissue stem cells, including those of the mammary gland, and proteins involved in this pathway 
are also reported to be perceptible and acting in human breast CSCs (cancer stem cells), observed 
specifically in CD44+CD24 – Lin – cells (7).   
Once Hedgehog proteins are produced, they undergo modifications involving lipids 
within the secretory pathway.  Authors Evangelista, Tian, and de Sauvage specifically mention 
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some modifications in their article published in 2006: for example, cholesterol groups are known 
to be added to the carboxyl terminus of the protein, while palmitoyl groups are added to the 
amino terminus of the protein (8). Once the Hedgehog proteins have proceeded through the 
secretory pathway, and have been modified, a transmembrane protein called Dispatched (Disp) 
dictates release of the Hedgehog protein from the cell (8).  The binding of a Hedgehog protein to 
the transmembrane receptor Patched (PTCH) activates the signaling cascade of the pathway in 
the receiving cell, enabling the GPCR-like transmembrane protein Smoothened (SMO) to 
relocate from the cytoplasm to the membrane of the cilia where Patched is found (8).  Two 
regulating proteins called Hedgehog interacting protein (Hip), and growth arrest-specific protein 
(Gas-1), are able to isolate Hedgehog proteins following binding, and largely determine how 
much of the Hedgehog protein is accessible and can interact with the receptor Patched (9). 
Early studies suggest Hip and Gas1 are able to render Hedgehog proteins unavailable 
upon binding due to competition for binding sites, as Gas1 binding to Sonic Hedgehog and Sonic 
Hedgehog binding to Patched cannot occur simultaneously (10).  Cdo and Boc are two proteins 
thought to assist with Hedgehog ligand binding to the PTCH receptor.  Following activation by 
Hedgehog binding, SMO then interacts with a complex of proteins within the cytoplasm to 
activate glioma-associated (GLI) proteins that may then enter the nucleus; there are three GLI 
transcription factors (9). 
GLI1 is the fundamental activator of transcription and targets a diverse number of genes 
relevant to roles characteristic of most cancers, as well as feedback loops that influence activity 
within the pathway (8).  These include genes coding for Platelet Derived Growth Factor 
Receptor (PDGFR) and Myc, as well as Cyclins D1 and D2, known to be involved with cell 
proliferation.  Other GLI1 targets include the gene coding for the anti-apoptotic protein BCL2, 
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genes that code for VEGF and ANG, which are involved in generating nourishing vessels to 
tumors, genes coding for SNAIL and MMP9, which are associated with the epithelial-
mesenchyme transition that is necessary for cell migration; authors Kwon, et al. also report that 
GLI1 is able to up-regulate expression of MMP11 in triple negative breast cancer cells and ERa-
negative breast cancer cells, promoting metastasis by increasing migration, as well as invasion 
(11). Genes coding for NANOG and SOX2, which are implicated in self-renewal, are also 
known targets of GLI1.  Products involved with feedback regulation of the pathway include the 
targets Hip, PTCH, and GLI1 (8).  GLI3’s role is known to be that of a transcriptional repressor, 
and GLI2’s function may be to aid, or repress transcription, contingent upon modifications that 
result in an abbreviated form of the protein (8). 
Without the Hedgehog signal, PTCH inhibits the action of SMO, preventing its relocation 
to the cell membrane and retaining it in the cytoplasm (9).  Protein kinase A, GSK-3, and Ck1 all 
interact with GLI through phosphorylation, which prompts selective proteolytic cleavage of GLI, 
regulated by the proteasome (9).  The abbreviated form of the GLI protein, GLI3, then acts to 
repress transcription of Hedgehog pathway genes.  Another protein that plays a prominent role in 
regulation for this pathway is called Suppressor of Fused (SUFU); SUFU is able to prevent 
transcription of genes through its ability to bind cytoplasmic GLI proteins as well as GLI 
proteins within the nucleus (9).  It is worth mentioning that in the vertebrate pathway, proteins 
equivalent to Fused, Costal2, and Ci appear to be absent, unlike in the well-studied Drosophila 
model for the Hedgehog pathway. 
Abnormal initiation of Hedgehog pathways in adult cells (long after crucial 
development), or aberrant and continuous activation during tissue repair, impact many different 
cancers through mutations resulting in elevated levels of expression of Hedgehog proteins, or 
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mutations within the pathway (9).  Central characteristics of all cancers, including proliferation, 
anti-apoptotic or cell survival strategies, and the ability to form metastases have all been 
attributed to inappropriate activation of the Hedgehog pathway, resulting from excessive 
expression levels of Hedgehog proteins; overexpression of these ligands has reportedly been 
traced in a plethora of cancer cell lines and tumors from pancreatic cancers, prostate cancers, 
small cell lung cancers, and gastric cancers, among others (8).  Lee, et al. mention the mutation 
H134Y occurring in the Sonic Hedgehog protein.  This mutation may bring about tumorigenic 
effects from a lowered capacity to bind the regulatory protein Gas1, leaving an overabundance of 
Sonic Hedgehog, inducing large increases in signaling and ultimately leading to uncontrolled 
growth (10). 
Mutations occurring within the Hedgehog pathway have been reported to occur in several 
types of cancerous tumors; for example, mutations rendering PTCH1 inactive and unable to 
repress SMO in the absence of Hedgehog protein allow inappropriate initiation of the signaling 
pathway (9).  This type of mutation is culpable in Gorlin syndrome, where patients are made 
particularly vulnerable to basal cell carcinomas and unusual tumor types, including 
medulloblastomas and rhabdomyosarcomas (9).  Basal cell carcinomas are also known to occur, 
with cogently fewer cases, when a particular mutation affecting SMO allows it to evade 
suppression by PTCH1, and multiple mutations found in sporadic medulloblastoma occur in 
PTCH1, SMO, and Supressor of Fused proteins (9).   
Notch Signaling  
Notch1-Notch4 are four transmembrane receptors that serve as the entry point for another 
molecular signaling pathway of critical significance in development (specifically regarding 
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signaling for lateral inhibition and cell fate), as well as having diverse and impactful roles in 
cancers (12).  In cancers, aberrant signaling of this pathway is likely to affect cell fate and 
prevent cells from differentiating or maintain them in a proliferative mode (12).  Initiation of this 
pathway occurs when Notch receptors respond to ligands Delta-like (Delta-like1, 3, and 4) and 
Jagged (Jagged1 and Jagged2); these ligands are from a family of proteins known as Delta, 
Serrate and Lag-2, or DSL (12). 
A series of proteolytic modifications to the Notch receptor transpires outside of the cell 
and within, following recognition of a DSL ligand (12).  The extracellular domain of Notch 
undergoes a proteolytic cleavage event by a protein known as a disintegrin and metalloprotease 
(ADAM), while the domains within the cell are subjected to a series of cleavage events that 
prepare the intracellular domain: the main intracellular cleavage event is carried out by the 
proprotein convertase furin, then the cytoplasmic domain undergoes further cleavage by a 
complex containing g-secretases Presenilin and Nicastrin, before the truncated form of the Notch 
protein, or Notch intracellular domain (NICD) is free to enter the nucleus and affect transcription 
via interaction with the Cb binding factor (CBF1) family of transcription factors (12). 
The effects of Notch signaling are diverse, and depend on NICD and CBF1 interactions 
with various protein complexes that either act as corepressors or coactivators of transcription 
(12).  SKIP (Ski-interacting protein) is a protein that binds to CBF1 and is reported to have a 
dual role in the presence of Notch; SKIP can behave as a corepressor of transcription with SMRT 
(Silencing Mediator for Retinoid and Thyroid hormone receptor) to recruit histone deacetylases 
that contribute to repression, and SKIP is also reported to behave as a coactivator of transcription 




Notch signaling may stimulate or quell a number of vital cellular processes or actions 
including determination of cell fate and differentiation, proliferation, and apoptosis, and errant 
signaling through this pathway is known to contribute to a variety of diseases, including cancers 
(14).  Among the many genes targeted for transcription by CBF1 factors are Hes1, Hes5, and 
Hey1 (known for their roles in repression of transcription), as well as several others, many of 
which are associated with cancers; these include genes encoding c-myc, cyclin D1, NFkB2, and 
bcl-2, as well as Notch1 and Notch3 (13).  As mentioned earlier, c-myc and Cyclin D1 are 
associated with cell cycle progression (D-cyclins complex with cdk4 and cdk6 to stimulate 
quiescent cells in G0 to begin the cell cycle), while bcl-2 is an antiapoptotic protein.  NFkB2 is 
one of a family of several NFkB proteins that play a role in immune response and are known to 
launch responses to both stress and chronic inflammation; an overabundance of signaling 
through NFkB pathways has also been reported in cancers (14). 
Under circumstances where the Notch pathway has not been initiated by DSL ligands, 
and NICD is not present, CBF1 proteins function to repress transcription (12).  Additional 
proteins reported to act as corepressors interacting with CBF1 include SHARP (SMRT and 
HDAC associated repressor protein), KyoT2, and CIR (CBF1 interacting corepressor) (13).  
Evidence for a distinctly separate route through the Notch pathway independent from that 
described above, has been elucidated in studies of Drosophila.   Brennan and Brown (12), report 
this signaling route makes use of other Notch receptor domains and is conditional on the 
involvement of a negative regulator protein present within the cytoplasm known as Deltex.  It 
has been suggested that a vertebrate protein equivalent to Deltex may participate in a similar role 
in humans; evidence suggests this route ultimately functions to abolish cell differentiation, 
inhibit the actions of Jun-N kinase (JNK) and also CREB binding protein (CBP) that works to 
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aid in activation of transcription, as well as repressing transcription of genes normally targeted 
downstream of the Wnt signaling pathway (12).   
It is known that Notch proteins can act as products of protooncogenes (15).  In addition to 
these early findings, further studies have established a potential role for Notch signaling in cell 
fate determination during normal development of human mammary tissue; these studies also 
established that signaling through this pathway is able to significantly increase mammary stem 
cell proliferation (15).  This study suggests inappropriate Notch signaling could be implicated in 
breast cancers through deregulating self-renewal of mammary stem cells (15).  
Metastasis: Progression of Cancers 
Metastasis, which is the hallmark of a malignant tumor, is the most dangerous and 
inscrutable feature of cancers, causing problematic challenges for successful treatment and being 
culpable in most cancer deaths.  Little is actually known about what precisely transpires to make 
a specific cancer cell attempt to migrate from its primary tissue site.  The first of several 
difficulties encountered by the migrating cancer cell is breaking through its existing tissue 
boundaries.  A cancer cell must have acquired certain features that distinguish it from other 
cancerous cells within the initial tumor, allowing it to fulfill this role as it responds to local 
stimuli (via paracrine signaling) and undergoes epithelial-mesenchyme transition.  One of these 
features is the likely loss of E-cadherin (crucial for cell-to-cell adhesion via specialized 
recognition), as well as the likely initiation of expression for select mesenchymal proteins, such 
as N-cadherin, vimentin, fibronectin, matrix metalloproteases (MMPs) and PDGFR (16).   
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  Vimentin is an intermediate filament protein contributing to structures in certain cells 
like fibroblasts, while N-cadherin is another member of the family of proteins critically involved 
with cell-to-cell adhesion.  Fibronectin is an ECM protein composed of a dimer with subunits 
connected by cross-linking disulfide bonds; type III fibronectin binds to cell surface integrins, 
affixing matrix protein to the cellular cytoskeleton.  Platelet Derived Growth Factor Receptor 
(PDGFR) is normally heavily involved in wound healing and associated with cell proliferation, 
as mentioned earlier.  MMPs, or matrix metalloproteases, are a class of proteolytic enzymes that 
work extracellularly to locally degrade fundamental matrix components such as collagen or 
laminin, or fibronectin.  Some MMPs work with high specificity, while others are bound to the 
membrane where they are needed, or limited by tissue inhibitors of metalloproteases (TIMPs).  
MMPs are essential for a cell to extricate itself from the extracellular matrix, allowing for cell 
migration.  
The next difficulty presented to the migrating cancer cell that has encroached normal 
tissue borders is to reach or secure a path that will allow escape of its primary site.  Macrophages 
are reported to play a vital role in facilitating the cancer cell’s successful migration into blood 
vessels it will utilize on its path (17).   It must then survive through the lymph or blood 
circulation to reach a secondary site, where it may entrench itself and successfully invade new 
tissue borders.  In order to survive this journey, the migrating cancer cell must effectively evade 
immune response components; for example, within the bloodstream, platelets are instrumental in 
shielding the cancer cell from recognition by Natural Killer (NK) cells (17).  
Invasion requires use of the same degradation strategy needed for escape from the tissue 
borders of its primary site.  If this has been accomplished, then micrometastases must be 
established and suitably maintained for cancer cell survival, growth, and colonization or 
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development of a new tumor at the second site.  This is a series of difficulties most migrating 
cancer cells are unable to navigate and survive.  Lacking constant signaling and nourishment 
emanating from the tumor microenvironment of the primary tumor site, these challenges most 
often prove fatal and the migrating cancer cells die off before reaching a new site, or the 
micrometastases cluster fails to establish itself and is unable to grow and eventually dies.  Our 
hypothesis is centered around the question of what prompts the cancer cell to undertake the 
initial challenge of migration. 
We hypothesize that cancer cell migration occurs in order for a cell to escape harsh 
stresses imposed by a tumor microenvironment that has become too inhospitable to support it.  
Stresses within a tumor microenvironment are created with the involvement of multiple factors, 
over time.  Among the stresses encountered are hypoxic conditions, an acidic pH, and, possibly, 
elevated temperature (17).  Accumulating mutations and genetic dysregulation, together with 
defective DNA repair mechanisms, and aberrant cell survival mechanisms contribute to 
uncontrolled cell proliferation and tumor growth in cancers (18, 17). Although tumor 
microenvironments are known to change over time to favorably support a tumor as it increases in 
size, tumor growth may occur at a faster rate than the development of vasculature that will reach 
tumor cells located within the innermost areas of the tumor (17).  Hypoxia is introduced as cells 
are denied necessary oxygen, heat stress occurs within tumors as cells growing and proliferating 
uncontrollably may begin to elevate core temperatures inside of the tumor, and increased 
metabolic activity may begin to alter pH, creating conditions that are more acidic (17, 18).  Some 
stresses encountered within the tumor microenvironments of cancer cells may impact or 
determine crucial adaptive cellular responses contributing to levels of expression for miRNAs 
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that can have broad and cumulative results with respect to the invasiveness of cancer cells (18).  
These results may affect the onset or progression of metastatic disease. 
miRNAs 
miRNAs are small, single-stranded, non-coding RNAs that base pair with specific 
mRNAs, often affecting levels of protein expression within cells either by activating or inhibiting 
translation.  miRNAs were originally identified in 1993, and since that time at least 2500 human 
miRNAs have been discovered.   Recent studies project up to 60% of protein coding genes are 
subject to regulation by miRNAs; more than half of genes that code for miRNAs are known to be 
located in areas of the human genome frequently associated with cancers (19).  miRNAs are 
known to be products of protooncogenes and tumor suppressors, and have been heavily studied 
due to their crucial roles in cancers.  miRNAs are also known to have significant involvement in 
roles connected with normal development of breast tissue, as well as promotion or suppression of 
invasive disease in breast cancers.  Many important cellular processes are subject to the 
regulatory actions of miRNAs with diverse and wide-ranging impacts.   
miRNAs are produced from a pre-miRNA transcript known to undergo processing by at 
least two ribonucleases: Drosha and Dicer.  RNA-Induced Silencing Complex (RISC) then 
becomes active, and Argonaut (AGO) proteins can then degrade the passenger strand.  miRNAs 
most often target specific AU-rich sequences within the 3’ UTR of a specific mRNA.  
Interactions between miRNAs and their target mRNAs do not require precise complementarity; 
consequently, a single miRNA may potentially target a vast number of mRNAs (19).  miRNAs 
are also known to regulate gene expression through transcriptional repression by initiating action 
of the RNA Induced Transcription Silencing (RITS) complex, which prompts a conversion to 
transcriptionally inert heterochromatin. 
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Many studies have been performed to examine miRNA expression levels in relationship 
to invasive breast cancers compared with healthy breast tissue.  Some specific miRNAs 
associated with metastatic disease were found to have expression levels comparable to those 
demonstrated during normal phases of healthy tissue development characterized by large 
proliferation rates (19).  Le Quesne, et al. offer examples taking place during phases of puberty 
and gestation, where proliferation in ductal and alveolar breast tissues are known to be 
dramatically increased (19). 
Classification of breast cancers based on extensive gene expression profiles, or 
‘signatures’ performed with microarrays, have allowed researchers to categorize or establish 
subtypes for breast tumors (20, 21).  Authors Hu, et al. explain that the subtypes that most breast 
tumors fall into include Luminal A, Luminal B, Basal-like, Her2+, and normal breast-like, and 
then go on to discuss the significance of these large-scale miRNA expression studies (21).  The 
article by Hu et al. details how the subsequent identification of subtypes not only sheds light on 
breast cancer etiology as well as associating pathological characteristics with certain tumor 
types, but has crucial clinical relevance regarding specific targeted treatment approaches and 
patients’ prognoses (21).       
Early observations that clarified various roles for miRNAs within normal healthy tissues 
have allowed for better comprehension regarding the impacts of gene dysregulation in the onset 
and promotion of disease.  Previous studies relating to invasive breast cancers demonstrate 
particular miRNAs to be up-regulated, and certain others to be down-regulated.                                                                                                                                                                                                       
 Previous studies reflect down-regulated levels of expression for miR-145 in breast 
cancers, and these lowered expression levels have been associated with several pathological 
aspects of metastatic disease (22).  miR-145 is known to participate in a wide range of cellular 
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processes and functions significant in many different cancers, and its numerous roles help to 
make it robust in its tumor suppressor effects (22).  Multiple studies examining miR-145 identify 
its involvement in apoptosis, cancer cell differentiation, proliferation, tumor growth, 
angiogenesis, invasion, metastasis, as well as its role as a diagnostic and prognostic indicator; it’s 
therapeutic potential has also been identified (23, 24).  miR-145’s tumor suppressive behavior is 
tissue and tumor-type specific; targets and functions vary in differing metastatic diseases.  In 
breast cancers, several oncogenic targets for miR-145 include ER-a, c-Myc, RTKN, MUC1, 
FSCN1, OCT4, N-RAS, MMP11, Rab27a, and HBXIP (22, 24, 25). 
A study that examined the effects of elevated expression levels for miR-145 has reported 
lowered levels of expression for EF-a, and higher levels of expression for p53 (known to also be 
regulated by miR-34), leading to a greater presence of the cleaved form of PARP and higher 
levels of the proapoptotic proteins, PUMA and p21 (23, 24).  One study concluded miR-145 
expression ultimately induces apoptosis in breast cancer cells (24).  c-Myc is associated with 
proliferation, but when Myc expression is targeted by miR-145 the cell cycle is arrested (23).  c-
Myc is also associated with apoptosis, as well as invasion in breast cancers, while RTKN is 
another target associated with proliferation.  Mucin1 (MUC1) is associated with invasive and 
metastatic features of breast cancer, occurring as a result of its ability to interact with b-catenin; 
when MUC1 is successfully targeted by miR-145, cancerous migration from breast to lung tissue 
is reportedly checked (23).  Fascin homologue 1 (FSCN1) is a protein known to bind with actin 
and is reported to be associated with invasion in breast cancers as well.  Octamer binding 
Transcription factor 4 (OCT4) is associated with cell differentiation and CSCs, while N-RAS 
promotes both cell division and angiogenesis in breast cancers (23).   
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MMP11 is associated with invasion and metastases, and Rab27a is reported to advance 
tumor growth as well as metastasis in breast cancers (25).  New evidence portrays Hepatits B X-
interacting protein (HBXIP) as a suspected target of miR-145 in a recently published study, and 
it has been reported to act as an oncogenic protein in breast cancers with functions relating to cell 
proliferation and invasion (24). 
miR-330-3p is reported to be upregulated and to function as the product of a 
protooncogene in breast cancers.  miR-330-3p has been found to promote breast cancer 
metastases, and is potentially useful as a biomarker; due to its overexpression, patients’ distant 
relapse-free survival is found to be decreased, making it a prognostic indicator (25).  Mesci, et al. 
explain that miR-330-3p has roles in various other metastatic disease (including esophageal and 
lung cancer, as well as glioblastoma), and that potential miR-330-3p targets involved in 
proliferation and invasion in other cancers include CCBE1, PDCD4, SH3GL2, EGR2 (25).  
 Although few targets of miR-330-3p have been identified with respect to invasive breast 
cancers to date (compared to more extensively studied miRNAs), it has recently become of 
interest as an important topic of study, and further research is needed to gather a better 
perspective of its roles in breast cancers.  One of miR-330-3p’s direct targets, Collagen and 
Calcium Binding EGF Domains 1 (CCBE1), a protein previously studied in relationship to other 
disease states, has recently been found to have tumor suppressive action in breast cancers; 
studies report that its silencing can be correlated with lower survival rates (25).     
For this investigation, heat and hypoxic stresses have been introduced in three cultured 
breast cancer cell lines: MCF7, MB468, and MB231.  MCF7 breast cancer cells are estrogen 
receptor positive (ER+) and progesterone receptor positive (PR+), while MB468 and MB231 
breast cancer cells are triple negative for estrogen, progesterone, and human epidermal growth 
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factor 2 receptors (ER-, PR-, and HER2-).  Triple negative breast cancer cells are known to 
demonstrate aggressive invasiveness, and triple negative breast cancers present unique 
challenges for treatment.  This study was undertaken in order to examine the impact of heat and 
hypoxic stresses encountered within the tumor microenvironment for endogenous expression 
levels of miR-145 and miR-330-3p.  We also wanted to analyze the effects these altered miRNA 
expression levels have on the invasiveness of breast cancer cells, in order to explore whether the 




































MCF7, MB468, and MB231 breast cancer cell lines were obtained from Dr. Jessica Kelts 
(Department of Chemistry and Biochemistry at the University of Michigan-Flint).  Cells were 
thawed and cultured in DMEM medium with 10% FBS (Fetal Bovine Serum) supplemented with 
sodium pyruvate, non-essential amino acids, and fungicidal and bactericidal agents 
amphotericin-B (0.25 µg/ml), and gentamicin (50 µg/ml), respectively.  Media prepared for 
MCF7 cells was also supplemented with insulin (10 µg/ml). 
Cell Preparation and Treatment 
 
MCF7, MB468, and MB231 cells were initially plated in P60 culture dishes (100,000 
cells per dish).  Cells were allowed to adhere overnight.  Then, two dishes were placed under 
normal conditions (37 degrees Celsius and ambient oxygen), two dishes were exposed to heat 
stress of 40 degrees Celsius, two dishes were exposed to hypoxic stress of 3.5% oxygen, and two 
dishes were exposed to both heat and hypoxic stress conditions at 40 degrees Celsius and 3.5% 
oxygen.  Cells were then incubated for 96 hours under each condition. 
miRNA Extraction 
 
Immediately following the 96-hour incubation, cells were lysed and miRNA extractions 
were performed using the miRNA isolation and enrichment protocols from the mirVana kit (Life 







The miRNA Quantification Assay was performed using the Quant-IT kit (Life 
Technologies).  The microplate was prepared by loading two wells from the first set of 
extractions, then two wells from the second set of extractions for each cell line, in a separate row 
for every condition, beginning with row B.  The first row of the microplate (row A) contained 
the standards. Fluorescence values obtained from the microplate reading were used to generate a 
standard curve using Excel software in order to determine concentration.  Concentrations of the 
experimental samples were determined by using the equation of the line generated by the 
standards. 
Reverse Transcription 
Reverse transcription was performed using the Taqman miRNA RT kit (Life 
Technologies).  10 ng RNA was used per reaction in order to obtain cDNA samples from both 
sets of samples for each condition in all cell lines.  Volumes per reaction were sufficient to load 
cDNA for subsequent Real Time PCR reactions in triplicate.   
Real Time PCR 
Real Time PCR amplification was performed using Taqman miRNA assays (20x primers 
specifically prepared for miR-145 and miR-330-3p) and Taqman PCR mastermix purchased 
from Life Technologies.  All samples were then plated in triplicate.  DDCT analysis was utilized 
to examine results obtained from Real Time PCR performed to establish miRNA expression 
levels following exposure to stress conditions.  Expression of each miRNA under each condition 
was normalized to the U6 small nuclear RNA control, giving a ΔCt value.  This DCT value was 
compared against the DCT values obtained for each sample for normal conditions, giving a ΔΔCt 
value.  This value represents the expression of each miRNA in each condition compared to the 
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U6 control and the cells grown under normal conditions, with expression levels being equivalent 
to 2ΔΔCt.  Positive values thus indicate an increase in expression, while negative values indicate a 
decrease in expression.   
Invasion Assays 
 
Invasion assays were performed using Matrigel invasion chambers obtained from Fisher 
Scientific (Pittsburgh, PA).  MCF7 and MB468 breast cancer cells were resuspended in freshly 
prepared serum-free medium prior to being loaded into chambers. 25,000 and 50,000 cells were 
plated per chamber for each condition and cells were incubated for 96 hours: two chambers 
contained cells exposed to normal conditions (37 degrees Celsius, and ambient oxygen), two 
chambers contained cells subjected to heat stress at 40 degrees Celsius, two chambers contained 
cells exposed to hypoxic stress of 3.5% oxygen, and two chambers contained cells exposed to 
both heat and hypoxic stresses (40 degrees Celsius and 3.5% oxygen).  Cells that were able to 
degrade the artificial extracellular matrix and migrate to the bottom of the chamber were stained 
with a solution of 0.9% crystal violet in 10% methanol.  In order to quantify the invasion assays, 
each invasion chamber was photographed by quadrant, then systematically counted using ImageJ 
software in order to examine the invasiveness of MCF7 and MB468 breast cancer cells under the 













MCF7, MB468, and MB231 cells were plated in P60 culture dishes (100,000 cells per 
dish) and allowed to adhere overnight before undergoing a 96-hour incubation under stress 
conditions. Two dishes were placed under each condition: normal conditions (37 degrees Celsius 
and ambient oxygen), heat stress (40 degrees Celsius), hypoxic stress (3.5% oxygen), and dual 
stress (40 degrees Celsius and 3.5% oxygen).  Cells were lysed, and miRNA was extracted 
immediately upon completion of the 96-hour incubation period. 
miRNA was quantified and reverse transcription was performed with the Taqman 
miRNA RT kit purchased from Life Technologies; average values for concentrations of 
quantified miRNA samples are listed in appendix 1.  Kruskal-Wallis analysis was performed for 
miRNA concentrations, using SPSS statistical software; median miRNA concentrations (µg/ml) 
under normal conditions, heat stress, hypoxic stress, and dual stress conditions were compared 
within each of the three breast cancer cell types.  A significant difference in median miRNA 
concentrations among cells exposed to normal and stress conditions can be observed within each 
cell type, and Kruskal-Wallis analyses can be viewed in appendix 2, (MCF7 p<0.05, MB468 
p<0.01, and MB231 p<0.05).  These results support the prediction that overall miRNA 
concentrations differ within breast cancer cells subjected to stress compared with cells under 
normal conditions.   
Reverse transcription reactions were performed for each condition with miRNA extracted 
from MCF7, MB468, and MB231 breast cancer cells.  Taqman miR-145 and miR-330-3p assays 
(20X) and Taqman Universal PCR Mastermix (Life Technologies) were used, as well as the 
cDNA produced from reverse transcription reactions, in order to perform real time PCR 
amplification of miR-145, miR-330-3p, and the snRNA U6, which served as the reference gene.  
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Some issues encountered during this experiment involved the exhaustion of necessary reagents 
and of original miRNA extraction samples, limiting or preventing collection of data for certain 
replicates.  Exceptions to our experimental parameters include the elimination of the heat stress 
condition in the replicate PCR run for the 2nd sample-set of MCF7 extractions (due to total 
depletion of the RNA sample, heat stress samples could not undergo reverse transcription); also 
eliminated were MB468 dual stress samples from sample-set 1 for the first and replicate PCR 
runs.  Additionally, only one sample-set of extractions could be examined for MB231 cells, due 
to exhaustion of reagents required for real time PCR amplification.  A first and replicate run of 
reverse transcription and real time PCR was performed for 1 set of miRNA extractions from 
MB231 breast cancer cells. 
Analysis of Real Time PCR 
Real time PCR reactions were done in triplicate.  Ct values are listed in Tables 2, 3, and 
4.  The two closest Ct values were averaged for each condition from every cell type for U6, miR-
145, and miR-330-3p reactions, before determining the ∆Ct.  Ct values were then normalized to 
the U6 small nuclear RNA control to determine ∆Ct values for each condition, from every 










Cell Type RXN Condition Sample-Set PCR Run Ct Value 
      
MCF7 U6 Normal Set 1 First  16.05 
MCF7  U6 Normal Set 1 Replicate 21.63 
MCF7 U6 Normal Set 2 First 21.95 
MCF7 U6 Normal Set 2 Replicate 22.85 
MCF7  U6 Heat Set 1 First 17.72 
MCF7  U6 Heat Set 1 Replicate 18.93 
MCF7 U6 Heat Set 2 First  19.66 
MCF7 U6 Heat Set 2 Replicate  * 
MCF7  U6 Hypoxia Set 1 First  19.96 
MCF7 U6 Hypoxia Set 1 Replicate 19.58 
MCF7 U6 Hypoxia Set 2 First 29.78 
MCF7 U6 Hypoxia Set 2 Replicate 17.53 
MCF7 U6 Dual Stress Set 1 First  15.46 
MCF7 U6 Dual Stress Set 1 Replicate 15.81 
MCF7 U6 Dual Stress Set 2 First 23.10 
MCF7 U6 Dual Stress Set 2 Replicate 18.56 
MCF7  miR-145 Normal Set 1 First  32.50 
MCF7 miR-145 Normal Set 1 Replicate  33.27 
MCF7 miR-145 Normal Set 2 First 30.92 
MCF7 miR-145 Normal Set 2 Replicate 29.86 
MCF7 miR-145 Heat Set 1 First 29.35 
MCF7  miR-145 Heat Set 1 Replicate  30.79 
MCF7 miR-145 Heat Set 2 First 28.63 
MCF7 miR-145 Heat Set 2 Replicate * 
MCF7  miR-145 Hypoxia Set 1 First 30.65 
MCF7 miR-145 Hypoxia Set 1 Replicate  30.68 
MCF7 miR-145 Hypoxia Set 2 First  32.09 
MCF7 miR-145 Hypoxia Set 2 Replicate 32.20 
MCF7  miR-145 Dual Stress Set 1 First  29.74 
MCF7  miR-145 Dual Stress Set 1 Replicate  31.05 
MCF7 miR-145 Dual Stress Set 2 First 30.56 
MCF7 miR-145 Dual Stress Set 2 Replicate 30.70 
MCF7 miR-330-3p Normal Set 1 First 33.21 
MCF7 miR-330-3p Normal Set 1 Replicate 31.99 
MCF7 miR-330-3p Normal Set 2 First 28.99 
MCF7 miR-330-3p Normal Set 2 Replicate 28.87 
MCF7 miR-330-3p Heat Set 1 First 28.86 
MCF7 miR-330-3p Heat Set 1 Replicate 29.90 
MCF7 miR-330-3p Heat Set 2 First 28.35 
MCF7 miR-330-3p Heat Set 2 Replicate  * 
MCF7 miR-330-3p Hypoxia Set 1 First  30.26 
MCF7 miR-330-3p Hypoxia Set 1 Replicate 29.63 
MCF7 miR-330-3p Hypoxia Set 2 First 29.35 
MCF7 miR-330-3p Hypoxia Set 2 Replicate 30.01 
MCF7 miR-330-3p Dual Stress Set 1 First 28.91 
MCF7 miR-330-3p Dual Stress Set 1 Replicate 29.59 
MCF7 miR-330-3p Dual Stress Set 2 First 27.56 
MCF7 miR-330-3p Dual Stress Set 2 Replicate  30.09 
 
Table 1     Ct Values from Real Time PCR Amplification of miRNAs from 
MCF7 breast cancer cells 
 
Real Time PCR reactions were performed in order to examine expression levels for miR-145 and miR-330-3p in MCF7 breast 
cancer cells exposed to stress conditions.  All samples were run in triplicate, and three Ct values were collected for each sample 
in both miRNA extraction sets.  The two closest Ct values for every sample were averaged, and this is the value listed above.  
Each PCR run was then repeated (with fresh cDNA prepared from replicate RT reactions).  The U6 snRNA was used as the 
reference.  These Ct values were then used to determine the ∆Ct for each condition in MCF7 breast cancer cell miRNA 
extractions. 
*The condition for the Replicate Run for MCF7 Heat/Sample-Set 2 had to be eliminated, because the RNA sample from Set 2 




Table 2     Ct Values from Real Time PCR Amplification for miRNAs from 
MB468 breast cancer cells 
 
Real Time PCR reactions were performed in order to examine expression levels for miR-145 and miR-330-3p in MB468 breast 
cancer cells exposed to stress conditions.  All samples were run in triplicate, and three Ct values were collected for each sample 
in both miRNA extraction sets.  The two closest Ct values were averaged, and this is the value listed above.  Each PCR run was 
then repeated (with fresh cDNA prepared from replicate RT reactions).  The U6 snRNA was used as the reference.  These Ct 
values were then used to determine the ∆Ct for each condition in MB468 breast cancer cell miRNA extractions. 
*The Dual Stress condition for both the first and replicate PCR runs produced no amplification, as well as the miR-145 Hypoxia 
sample from the first sample-set during the replicate PCR run. 
 
 
Cell Type RXN Condition Sample-Set PCR Run Ct Value 
      
MB468 U6 Normal Set 1 First 24.55 
MB468 U6 Normal Set 1 Replicate 24.62 
MB468 U6 Normal Set 2 First 25.58 
MB468 U6 Normal Set 2 Replicate 27.24 
MB468 U6 Heat Set 1 First 20.33 
MB468 U6 Heat Set 1 Replicate 29.99 
MB468 U6 Heat Set 2 First 21.67 
MB468 U6 Heat Set 2 Replicate 20.24 
MB468 U6 Hypoxia Set 1 First 34.32 
MB468 U6 Hypoxia Set 1 Replicate 34.83 
MB468 U6 Hypoxia Set 2 First 32.66 
MB468 U6 Hypoxia Set 2 Replicate 31.14 
MB468 U6 Dual Stress Set 1 First * 
MB468 U6 Dual Stress Set 1 Replicate * 
MB468 U6 Dual Stress Set 2 First 19.41 
MB468 U6 Dual Stress Set 2 Replicate 20.06 
MB468 miR-145 Normal Set 1 First 38.34 
MB468 miR-145 Normal Set 1 Replicate 38.04 
MB468 miR-145 Normal Set 2 First 35.50 
MB468 miR-145 Normal Set 2 Replicate 38.20 
MB468 miR-145 Heat Set 1 First 32.07 
MB468 miR-145 Heat Set 1 Replicate 33.06 
MB468 miR-145 Heat Set 2 First 29.45 
MB468 miR-145 Heat Set 2 Replicate 30.05 
MB468 miR-145 Hypoxia Set 1 First 35.88 
MB468 miR-145 Hypoxia Set 1 Replicate * 
MB468 miR-145 Hypoxia Set 2 First 33.05 
MB468 miR-145 Hypoxia Set 2 Replicate 30.76 
MB468 miR-145 Dual Stress Set 1 First * 
MB468 miR-145 Dual Stress Set 1 Replicate * 
MB468 miR-145 Dual Stress Set 2 First 32.08 
MB468 miR-145 Dual Stress Set 2 Replicate 32.35 
MB468 miR-330-3p Normal Set 1 First 35.44 
MB468 miR-330-3p Normal Set 1 Replicate 33.99 
MB468 miR-330-3p Normal Set 2 First 33.18 
MB468 miR-330-3p Normal Set 2 Replicate 34.46 
MB468 miR-330-3p Heat Set 1 First 33.12 
MB468 miR-330-3p Heat Set 1 Replicate 33.55 
MB468 miR-330-3p Heat Set 2 First 30.84 
MB468 miR-330-3p Heat Set 2 Replicate 33.09 
MB468 miR-330-3p Hypoxia Set 1 First 36.89 
MB468 miR-330-3p Hypoxia Set 1 Replicate 37.54 
MB468 miR-330-3p Hypoxia Set 2 First 37.17 
MB468 miR-330-3p Hypoxia Set 2 Replicate 33.06 
MB468 miR-330-3p Dual Stress Set 1 First * 
MB468 miR-330-3p Dual Stress Set 1 Replicate * 
MB468 miR-330-3p Dual Stress Set 2 First 38.12 
MB468 miR-330-3p Dual Stress Set 2 Replicate 36.71 
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Cell Type RXN Condition Sample-Set PCR Run Ct Value 
      
MB231 U6 Normal Set 2 First 24.84 
MB231 U6 Normal Set 2 Replicate 18.38 
MB231 U6 Heat Set 2 First 21.36 
MB231 U6 Heat Set 2 Replicate 23.15 
MB231 U6 Hypoxia Set 2 First 20.95 
MB231 U6 Hypoxia Set 2 Replicate 28.15 
MB231 U6 Dual Stress Set 2 First 17.08 
MB231 U6 Dual Stress Set 2 Replicate 19.32 
MB231 miR-145 Normal Set 2 First 35.21 
MB231 miR-145 Normal Set 2 Replicate 33.06 
MB231 miR-145 Heat Set 2 First 31.88 
MB231 miR-145 Heat Set 2 Replicate 32.71 
MB231 miR-145 Hypoxia Set 2 First 33.22 
MB231 miR-145 Hypoxia Set 2 Replicate 33.63 
MB231 miR-145 Dual Stress Set 2 First 32.99 
MB231 miR-145 Dual Stress Set 2 Replicate 32.78 
MB231 miR-330-3p Normal Set 2 First 30.55 
MB231 miR-330-3p Normal Set 2 Replicate 32.87 
MB231 miR-330-3p Heat Set 2 First 31.46 
MB231 miR-330-3p Heat Set 2 Replicate 32.16 
MB231 miR-330-3p Hypoxia Set 2 First 30.46 
MB231 miR-330-3p Hypoxia Set 2 Replicate 32.54 
MB231 miR-330-3p Dual Stress Set 2 First 31.05 
MB231 miR-330-3p Dual Stress Set 2 Replicate 33.16 
 
Table 3     Ct Values from Real Time PCR Amplification for miRNAs from 
MB231 breast cancer cells 
 
Real Time PCR reactions were performed in order to examine expression levels for miR-145 and 
miR-330-3p in MB231 breast cancer cells exposed to stress conditions.  All samples were run in 
triplicate, and three Ct values were collected for each sample from the second set of miRNA 
extractions (the second set of extractions were examined first, and upon completion of Real Time 
PCR reactions for this set of reactions, reagents had been exhausted preventing further PCR 
analysis).  The two closest Ct values were averaged, and this is the value listed above.  Each 
PCR run was then repeated (with fresh cDNA prepared from replicate RT reactions).  The U6 
snRNA was used as the reference.  These Ct values were then used to determine the ∆Ct for each 











∆∆Ct values were calculated by comparing the ∆Ct value for cells grown under normal 
conditions to the ∆Ct value for cells grown under each stress condition in miR-145 and miR-
330-3p reactions from each cell type, in order to examine the specific miRNA expression levels 
for breast cancer cells exposed to each stress condition.  ∆∆Ct values represent the expression of 
each miRNA (in each condition, compared with both the RNA control and normal conditions), 
and expression levels can be expressed as 2ΔΔCt; positive values are indicative of increases in 
expression and negative values are indicative of decreases in expression.  ∆∆Ct values have 
been averaged for every miRNA in each condition for each cell type and are listed in Tables 5 
(MCF7), 6 (MB468), and 7 (MB231). 
Expression levels for miR-145 have previously been found to be downregulated in breast 
cancer cells, and we hypothesized that expression levels would be downregulated in MCF7, 
MB468, and MB231 breast cancer cells exposed to stress conditions.  Additionally, we expected 
to find expression levels for miR-330-3p to be upregulated in MCF7, MB468, and MB231 breast 
cancer cells exposed to stress conditions.  ∆∆Ct values determined for miR-145 in MCF7 breast 
cancer cells were found to be positive under heat stress conditions at 40 degrees Celsius and 
under hypoxic stress at 3.5% oxygen (∆∆Ct 1.53 and 1.33, respectively); these data appear to 
suggest increased expression, which was unexpected.  ∆∆Ct values determined for miR-145 
reactions were, however, found to be negative in MCF7 cells exposed to dual stress conditions at 
40 degrees Celsius and 3.5% oxygen (∆∆Ct -1.26); these data appear to indicate downregulated 
expression, consistent with our expectations. 
Positive ∆∆Ct values were determined for miR-330-3p reactions in MCF7 cells exposed 
to heat and hypoxic stresses (∆∆Ct 1.25 and 2.05, respectively); these data seem to support our 
expectations for increased miR-330-3p expression under stress conditions.  Negative ∆∆Ct 
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values were determined for miR-330-3p reactions in MCF7 cells under dual stress conditions 
(∆∆Ct -2.64); this would suggest downregulation of miR-330-3p, which was unexpected. 
Some mixed findings can also be reported for MB468 cells: positive ∆∆Ct values were 
determined for miR-145 reactions in MB468 breast cancer cells exposed to heat stress, and 
hypoxic stress (∆∆Ct 3.92, and 11.03, respectively).  These data appear to suggest increased 
expression levels for miR-145 under heat stress, and under hypoxic stress.  Although this is not 
what we expected to find for cells exposed to individual stress conditions, ∆∆Ct values 
determined for miR-145 in MB468 cells under dual stress conditions were negative (∆∆Ct -
1.26), seeming to indicate downregulated expression for miR-145, which would be consistent 
with our hypothesis.  Surprisingly, negative ∆∆Ct values were reported for miR-330-3p 
reactions in MB468 cells exposed to heat stress (∆∆Ct -0.82), as well as for cells exposed to 
dual stress conditions (∆∆Ct -10.27); a positive ∆∆Ct of 5.84 was determined for miR-330-3p 
in MB468 cells subjected to hypoxic stress, which appears to support our expectation that 
increased expression of this miRNA would be observed under stress conditions.   
Positive ∆∆Ct values were determined for miR-145 reactions in MB231 cells subjected 
to heat stress (∆∆Ct 2.49), and hypoxic stress (∆∆Ct 3.65); although this is not what we 
expected to observe in cells exposed to individual stresses, cells exposed to dual stress conditions 
were determined to have a ∆∆Ct of -2.16.  This appears to support our expectations for 
decreased expression of miR-145 under stress conditions.  Seemingly in agreement with our 
expectation, positive ∆∆Ct values were reported for miR-330-3p reactions in MB231 cells under 
heat stress (∆∆Ct 0.55) and under hypoxic stress (∆∆Ct 3.15); this appears to suggest increased 
expression for miR-330-3p in cells exposed to these stresses.  Unexpectedly, a negative ∆∆Ct 
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value of -3.81 was calculated for miR-330-3p expression in MB231 cells subjected to dual stress 
























Cell Type RXN Condition  ∆∆Ct  Change in 
Expression 
     
MCF7 miR-145 Heat 1.53 2.89 
MCF7 miR-145 Hypoxia 1.33 2.51 
MCF7 miR-145 Dual stress -1.26 -2.39 
MCF7 miR-330-3p Heat 1.25 2.34 
MCF7 miR-330-3p Hypoxia 2.05 4.14 
MCF7 miR-330-3p Dual stress -2.64 -6.23 
 
Table 4     ∆∆Ct values for miR-145 and miR-330-3p in MCF7 breast cancer 
cells exposed to stress conditions 
 
Expression levels for miR-145 and miR-330-3p in MCF7 breast cancer cells exposed to stress 
conditions were examined through ∆∆Ct analysis following Real Time PCR.  All ∆∆Ct values 
obtained for MCF7 miRNA samples were averaged for each miRNA in each condition, and are 
listed here.  In MCF7 cells, ∆∆Ct values appear to reflect increased expression for miR-145 
under heat stress conditions at 40 degrees Celsius and also under hypoxic stress at 3.5% oxygen; 
however, under dual stress conditions at 40 degrees Celsius and 3.5% oxygen, miR-145 reactions 
in MCF7 cells seem to suggest down-regulation.  ∆∆Ct values appear to reflect increasing 
expression levels for miR-330-3p in MCF7 cells under heat stress (∆∆Ct 1.25) as well as 
hypoxic stress (∆∆Ct 2.05), although data seem to suggest lower levels of expression under dual 



























Cell Type RXN Condition ∆∆Ct Change in 
Expression 
     
MB468 miR-145 Heat  3.92 15.14 
MB468 miR-145 Hypoxia  11.03 2091.03 
MB468 miR-145 Dual Stress -2.04 -4.11 
MB468 miR-330-3p Heat -0.82 -1.77 
MB468 miR-330-3p Hypoxia  5.84 57.28 
MB468 miR-330-3p Dual Stress -10.27 -1234.75 
 
Table 5     ∆∆Ct values for miR-145 and miR-330-3p in MB468 breast cancer 
cells exposed to stress conditions 
   
Expression levels for miR-145 and miR-330-3p in MB468 breast cancer cells exposed to stress 
conditions were examined through ∆∆Ct analysis following Real Time PCR.  All ∆∆Ct values 
obtained for MB468 miRNA samples were averaged for each miRNA in each condition, and are 
listed here.  In MB468 cells, ∆∆Ct values for miR-145 reactions appear to depict increased 
expression levels under heat stress and seem to suggest an increase in expression under hypoxic 
stress; under dual stress conditions, miR-145 expression levels again appear to reflect down- 
regulation in MB468 cells.  miR-330-3p reactions in MB468 cells show slightly decreased 
expression levels under heat stress, although expression levels under hypoxic stress are shown to 




























Cell Type RXN Condition  ∆∆Ct  Change in 
Expression 
     
MB231 miR-145 Heat 2.49 5.62 
MB231 miR-145 Hypoxia 3.65 12.55 
MB231 miR-145 Dual Stress -2.16 -4.47 
MB231 miR-330-3p Heat 0.55 1.46 
MB231 miR-330-3p Hypoxia 3.15 8.88 
MB231 miR-330-3p Dual Stress -3.81 -14.03 
 
Table 6     ∆∆Ct values for miR-145 and miR-330-3p in MB231 breast cancer 
cells exposed to stress conditions 
 
Expression levels for miR-145 and miR-330-3p in MB231 breast cancer cells exposed to stress 
conditions were examined through ∆∆Ct analysis following Real Time PCR.  All ∆∆Ct values 
obtained for MB231 miRNA samples were averaged for each miRNA in each condition, and are 
listed here.  In MB231 cells, miR-145 reactions appear to have increased expression under heat 
stress and under hypoxic stress, while miR-145 expression seems to suggest down-regulation 
under dual stress conditions.  miR-330-3p reactions in MB231 cells appear to reflect 
upregulation of expression under heat stress and under hypoxic stress, although expression levels 


























Invasion Assays: Invasive Properties in Breast Cancer Cells Exposed to Stresses 
Matrigel invasion chambers were utilized for this portion of the project.  MCF7 and 
MB468 cells were plated at densities of 25,000 or 50,000 cells per well (cell densities were 
chosen based on optimal cell densities shown for previous studies with MCF7 cells and 
recommendations, calling for use of multiple densities, within the Matrigel protocol).  Cells were 
incubated for 96 hours.  Invasive cells are able to digest through a layer of extracellular matrix 
material and migrate through pores to the “outside” of the chamber.  Cells that remained in the 
chamber were scrubbed away, then cells that migrated through the matrix and pores were stained 
with a solution of crystal violet.  Invasion chambers were then individually photographed by 
quadrant through a microscope, and were systematically counted using Image J software in order 
to quantify the invasiveness of the cells under normal and stress conditions.  Invasion assay data 
are expressed as percentage cell migration in Figures 1 and 2.  Invasion data were collected and 
quantified as described above; percentage cell migration has not been supported by further 
statistical analysis, due to the scale of this portion of the experiment. 
We hypothesized that MCF7 and MB468 breast cancer cells exposed to heat, hypoxia, 
and dual stress conditions would prove to be more invasive than cells under normal conditions.  
In MCF7 cells (Figure 1), invasion chambers plated with 50,000 cells have 19% cell migration, 
and chambers plated with 25,000 cells reflect 15% cell migration under normal conditions.  
MCF7 cells exposed to heat stress reflect 15% cell migration for both chambers.  MCF7 cells 
exposed to hypoxic stress show a 5% cell migration in the chamber containing 50,000 cells, but 
have a 29% cell migration in the chamber plated with 25,000 cells.  MCF7 cells exposed to dual 
stress conditions have a 1% and 3% cell migration for the 50,000 and 25,000 cell chambers, 
respectively.  There was a marked increase in migrating MCF7 cells under hypoxic stress (29% 
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compared to 15% under normal conditions).  The remainder of the invasion assay data collected 
for MCF7 cells reflects equivalent or lesser percentage cell migration under heat stress, and 
appears to suggest lesser percentage cell migration under dual stress conditions compared with 
percentage cell migration found under normal conditions.   
Invasion assays performed with MB468 breast cancer cells (Figure 2), have 7% and 2% 
cell migration under normal conditions for chambers plated with 50,000 and 25,000 cells, 
respectively.  MB468 cells exposed to heat stress suggest a 42% cell migration for the 50,000 
cell chamber, and a 17% cell migration for the 25,000 cell chamber.  MB468 cells exposed to 
hypoxic stress have a 21% and 17% cell migration for the 50,000 cell and 25,000 cell chambers, 
respectively.  MB468 cells exposed to dual stress conditions have a 6% cell migration for the 
chamber containing 50,000 cells, and have a 7% cell migration for the chamber containing 
25,000 cells. 
Data collected for all invasion assays performed with MB468 breast cancer cells exposed 
to heat and hypoxic stresses appear to show increased percentage cell migration when compared 
with cells under normal conditions, in agreement with our hypothesis.  MB468 cells exposed to 
dual stress conditions seem to reflect slightly lesser cell migration (6%) for the 50,000 cell 
chamber when compared with cells under normal conditions (7%); the dual stress chamber 
containing 25,000 cells appears to have increased cell migration (7%) when compared with cells 





Figure 1     Percent Cell Migration per Condition for MCF7 Breast Cancer 
Cells 
 
25,000 and 50,000 cells (that were resuspended in serum-free medium) were plated per invasion 
chamber for each condition for assays performed with MCF7 breast cancer cells, and then 
subjected to a 96-hour incubation.  Two chambers were exposed to normal conditions (37 
degrees Celsius, and ambient oxygen), two chambers were exposed to heat stress at 40 degrees 
Celsius, two chambers were exposed to hypoxic stress at 3.5% oxygen, and two chambers were 
exposed to dual stress conditions (heat at 40 degrees Celsius, and hypoxic stress at 3.5% 
oxygen).  Invasive cells are able to digest through the matrix and migrate through the pores to the 
outside of the chamber.  Cells remaining in the interior of the chamber were scrubbed away, 
before migrating cells were stained with a crystal violet solution.  Chambers were then 
photographed by quadrant using a microscope and systematically counted, using ImageJ 
software.  Percentage cell migration data is not supported by further statistical analysis.  The 
invasion assay performed with MCF7 breast cancer cells under hypoxic stress (25,000 cell 
chamber) appears to have a marked increase in migrating cells (29%) compared with cells under 
normal conditions (15%), in agreement with our hypothesis.  The remainder of the invasion 
assay data collected for MCF7 cells seem to reflect equivalent or lesser percentage cell migration 
under heat stress and lesser percentage cell migration under dual stress conditions, compared 


















































Figure 2     Percent Cell Migration per Condition for MB468 Breast Cancer 
Cells 
 
25,000 and 50,000 cells (that were resuspended in serum-free medium) were plated per invasion 
chamber for each condition for assays performed with MB468 breast cancer cells, and then 
subjected to a 96-hour incubation.  Two chambers were exposed to normal conditions (37 
degrees Celsius, and ambient oxygen), two chambers were exposed to heat stress at 40 degrees 
Celsius, two chambers were exposed to hypoxic stress at 3.5% oxygen, and two chambers were 
exposed to dual stress conditions (heat at 40 degrees Celsius, and hypoxic stress at 3.5% 
oxygen).  Invasive cells are able to digest through the matrix and migrate through the pores to the 
outside of the chamber.  Cells remaining in the interior of the chamber were scrubbed away, 
before migrating cells were stained with a crystal violet solution.  Chambers were then 
photographed by quadrant using a microscope and systematically counted, using ImageJ 
software.  Percentage cell migration data is not supported by further statistical analysis.  Data 
collected for all invasion assays performed with MB468 breast cancer cells exposed to heat and 
hypoxic stresses appears to have increased percentage cell migration when compared with cells 
under normal conditions, in agreement with our hypothesis.  MB468 cells exposed to dual stress 
conditions seem to reflect slightly lesser cell migration (6%) for the 50,000 cell chamber when 
compared with cells under normal conditions (7%); the dual stress chamber containing 25,000 
cells appears to have increased cell migration (7%) when compared with cells under normal 
conditions (2%), in agreement with our hypothesis. 





















































Cancers are a deadly assortment of diseases characterized by uncontrolled cell 
proliferation and cell migration, invasion, and secondary tumor development in other areas of the 
body.  Metastatic disease presents obstacles for treatment, resulting in poor patient outcomes and 
lower rates of survival.  Our study explored the impact of heat and hypoxic stresses that occur 
within tumor microenvironments, on endogenous miRNA expression levels, and ultimately a 
cancer cell’s invasiveness.  We hypothesized that a cancer cell’s immediate tumor 
microenvironment may become too inhospitable to support it due to harsh stresses.  Some 
stresses encountered by the cancer cell may contribute, or be decisive in a cell’s adoption of 
adaptive responses, affecting miRNA expression and ultimately a cell’s invasiveness, which is 
impactful in both the onset and advancement of metastatic disease (17).   
Cancers are frequently associated with tumors characterized by a wide variety of 
mutations, occurring in two primary classes of genes: proto-oncogenes and tumor suppressor 
genes.  These mutations may affect gene expression and/or the function of their products.  
miRNAs are recognized as products of both proto-oncogenes and tumor suppressor genes, 
having important roles in cancers, and are known to exercise regulatory effects on many cell 
processes.  Through activation or inhibition of translation, miRNAs are able to influence protein 
expression; additionally, miRNAs may regulate expression of genes by means of repressing 
transcription.  Interactions between miRNAs and their target mRNAs do not require perfect 
precision, so a single miRNA may successfully target a large number of mRNAs, with 
significant and broad effects.   
The purpose of this study was to analyze miR-145 and miR-330-3p expression levels in 
breast cancer cells exposed to stresses known to occur in tumor microenvironments, then to 
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examine if any altered miRNA expression levels may have impacted the invasiveness of the 
cancer cells.  miR-145 is known to be the product of a tumor suppressor gene and is reported to 
be down-regulated in breast cancers, while proto-oncogene product miR-330-3p has been found 
to have increased expression in breast cancers.  For this investigation, cells from MCF7, MB468, 
and MB231 breast cancer cell lines were exposed to heat stress, hypoxic stress, and dual stress 
conditions.  We hypothesized that breast cancer cells exposed to stress would have lower levels 
of expression for miR-145, and increased levels of expression for miR-330-3p, when compared 
to miRNA expression analyzed in breast cancer cells grown in normal conditions. 
Some data collected for miRNA expression in this study appear to support our 
hypothesis, although mixed results are reported.  Data seem to reflect down-regulation of miR-
145 in samples from all three breast cancer cell lines exposed to dual stress conditions, in 
agreement with our hypothesis.  Surprisingly, miR-145 expression levels for cell samples 
exposed to heat and hypoxic stress appear to indicate increased expression in all three breast 
cancer cell lines for each of these individual stresses, which is a pattern we did not expect to 
observe. 
Down-regulation of tumor suppressor miR-145 has been associated with multiple facets 
of metastatic disease, and it has been suggested that this change in expression levels indicates 
advancement of disease (24).  Results of at least one study report that lower expression found in 
triple negative breast cancers may be attributed to effects of methylation on miR-145 (24). 
Although miR-145 targets and functions vary in different tissues and tumor types, several 
identified oncogenic targets of miR-145 are reported to be involved with invasion and metastasis, 
including MUC1, FSCN1, MMP11, and Rab27a, among others. 
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It has been reported that as a result of miR-145’s successful targeting of MUC1, 
migration of breast cancer cells to lung tissue is curtailed (19).  FSCN1 has also been implicated 
in breast cancer brain metastasis, and one study associates increased expression of FSCN1 with 
breast cancer cell migration and penetration of the blood brain barrier; this study also indicates 
the use of FSCN1 as a biomarker for potential breast cancer brain metastasis, one of the most 
treatment-resistant and deadly features of metastatic breast cancers (26).  MMP11, a member of a 
family of matrix metalloproteases known to contribute to metastasis, is a critical driver of cell 
migration and invasion and is over-expressed in breast and many other cancers.  Rab27a is also 
associated with advancing metastasis. Rab27a is reported to drive secretion of IGFII (insulin like 
growth factor II), which is then able to mediate the expression of several factors involved in both 
invasion and metastasis, including MMP9, UPA, VEGF, cyclin D1, cathepsin D, and p16 (27). 
These direct miR-145 targets and factors are only some that we know to be associated 
with invasion and metastasis in malignant breast cancers, although there may be many more 
direct targets as well as indirect factors that remain unknown.  A single miRNA could potentially 
have significant effects, as it may work on a large number of these targets.  miR-145 expression 
data suggest down-regulation of the tumor suppressor for all three breast cancer cell lines grown 
under dual stress conditions.  This indicates that key oncogenic targets associated with invasion 
and metastasis (in breast cancer cells) may not be silenced; for example, without regulation from 
miR-145, MUC1 and FSCN1 would be free to promote advancement of metastatic breast cancer 
cells to the lungs and brain, respectively.  This could have devastating consequences for 
treatment options and patient outcomes. 
Data suggest up-regulation of miR-330-3p expression for samples from all three breast 
cancer cell lines exposed to hypoxic stress, in agreement with our hypothesis.  Additionally, data 
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appear to suggest an increase in miR-330-3p expression in MCF7 and MB231 samples exposed 
to heat stress, also in agreement with our hypothesis.  Other data reflect some unexpected results 
for miR-330-3p expression levels in MB468 samples exposed to heat stress; expression levels for 
miR-330-3p exposed to heat stress seem to be decreased.  Although differences in behavior 
among different cell lines are known to occur, this is not a pattern we expected to observe.  
Additionally, we did not expect to see down-regulation of miR-330-3p expression in all three 
breast cancer cell lines exposed to dual stress conditions. 
Although protooncogene product miR-330-3p has not been studied as extensively, 
several direct targets relating to invasion and metastasis in various cancers have been identified 
for this miRNA.  In invasive breast cancers, CCBE1 is known to have tumor suppressive effects, 
and has been identified as one direct target specifically identified for miR-330-3p.  Data suggest 
upregulation of pro-metastatic miR-330-3p for all 3 breast cancer cell lines grown under hypoxic 
stress conditions, and for MCF7 and MB231 breast cancer cell lines grown under heat stress.  
Up-regulation of miR-330-3p in breast cancer cells indicates that the tumor suppressor actions of 
CCBE1 could be silenced, which has been correlated to lower patient survival rates.   
Issues mentioned earlier prevented sufficient data collection for further statistical analysis 
of miRNA expression data; consultation with statistician Dennis Viele (Biology Department, 
University of Michigan-Flint) confirmed sample sizes for miRNA expression data were 
insufficient for meaningful statistical analysis.  For this reason, we are not able to report these 
findings as conclusive, but believe they provide a basis for further scientific investigation. 
There are some limitations to bear in mind for this experiment, involving differences 
between conditions that occur within the body, and those that can be recreated in the lab.  The 
parameters of our experiment included a 96-hour incubation of cells subjected to specific 
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stresses, while the duration of exposure for cells subjected to stresses occurring within a tumor 
microenvironment could potentially persist for years in vivo.  Additional considerations 
associated with variability should also be weighed: possible dynamic fluctuations of those 
stresses within microenvironments, timing of introduction of additional or multiple stressors, and 
frequency of remodeling within microenvironments.   
We expected that invasion data collected for MCF7 and MB468 breast cancer cells would 
reflect higher percentage cell migration for cells exposed to stresses, compared with cells 
exposed to normal conditions.  Surprisingly, MCF7 breast cancer cells from the 50,000 cell 
chambers reflect a 19% cell migration under normal conditions, a 15% cell migration under heat 
stress, a 5% cell migration under hypoxic stress, and a 1% cell migration under dual stress 
conditions.  Although the MCF7 breast cancer cell line is known to be one of the least invasive 
lines, these data were not consistent with our expectations.  MCF7 breast cancer cells from the 
25,000 cell chambers reflect a 15% cell migration under normal conditions, a 15% cell migration 
under heat stress, a 29% cell migration under hypoxic stress, and a 3% cell migration under dual 
stress conditions.  While it was curious that cells grown under dual stress conditions did not 
behave as expected, we could speculate that perhaps there is a difference in the viability of these 
cells.  It may be possible that fewer cells survived the harsh dual stress conditions, impacting the 
number of migrating cells observed under dual stress conditions.  Although we expected to see 
greater percentage cell migration among MCF7 breast cancer cells exposed to stress conditions 
compared with normal conditions, data for cells from the 25,000 cell chamber subjected to 




Invasion data collected for MB468 breast cancer cells from 50,000 cell chambers reflect a 
7% cell migration under normal conditions, a 42% cell migration under heat stress, a 21% cell 
migration under hypoxic stress, and a 6% cell migration under dual stress conditions.  While it is 
curious that cells under dual stress conditions reflect a small decrease in percent cell migration 
compared with cells under normal conditions for 50,000 cell chambers, a dramatic increase in 
migration was observed for cells under heat and hypoxic stresses, consistent with our 
expectations.  MB468 breast cancer cells from 25,000 cell chambers reflect a 2% cell migration 
under normal conditions, a 17% cell migration under heat stress, a 17% cell migration under 
hypoxic stress, and a 7% cell migration under dual stress conditions.  These data are all in 
agreement with our hypothesis.  
We expected to find that breast cancer cells subjected to stresses found in tumor 
microenvironments would reflect up-regulation of miR-330-3p and prove more invasive. MCF7 
and MB468 breast cancer cell lines subjected to hypoxic stress suggest an increase in expression 
for miR-330-3p as well as increased invasiveness.   Although MCF7 breast cancer cells are 
known to be among the least invasive of breast cancer cell lines, an increase in percentage cell 
migration was observed for the 25,000 cell chambers under hypoxic stress conditions (versus 
cells under normal conditions), where our data seems to reflect higher levels of miR-330-3p 
expression.  This appears to suggest MCF7 breast cancer cells subjected to stress and having up-
regulated miR-330-3p expression are more invasive, consistent with our expectations. 
Data also appear to support our expectation that MB468 cells subjected to stress and 
reflecting increased expression levels of miR-330-3p would be more invasive; increases in 
percentage cell migration for both 25,000 and 50,000 cell chambers were observed for these cells 
under hypoxic stress, where miR-330-3p expression appears to be up-regulated.  Although we 
50 
 
had also predicted that breast cancer cells subjected to stress and having downregulated 
expression levels for miR-145 could be correlated with greater invasiveness, we only saw this 
reflected in the data for one cell line and condition.  Greater percentage cell migration was 
reported for MB468 cells subjected to dual stress conditions, as well as downregulation for miR-
145. 
Some data in this study support our predictions, and we feel these data present an 
interesting and potentially important direction for future scientific investigations.  Consideration 
for future studies should include protocol recommendations that necessitate plating for normal 
conditions with each stress condition for a simultaneous reaction run, in the event that PCR 
reactions are run separately for different stress conditions.  Future studies designed to further 






































Total miRNA Concentrations during stress conditions  
A miRNA quantification assay was performed using the Quant-IT kit from Life Technologies in 
order to confirm presence of miRNAs following extractions and to determine miRNA 
concentrations for each sample.  Row A of the microplate was loaded with miRNA standards 
provided as a component of the Quant-IT kit, while Rows B-E were loaded with unknown RNA 
samples.  Fluorescence values were obtained from a microplate reading, and Excel software was 
used to generate a standard curve (shown below), from which concentrations for unknown RNA 
samples were determined: first, amount versus fluorescence was plotted for the miRNA 
standards using Excel software, and the equation for the line y=4341.8x+700.58 was obtained 
and used to determine concentrations for the unknown RNA samples. This table (shown on the 
following page), lists concentrations for every sample condition for each of the 3 breast cancer 
cell lines.  All samples were plated in duplicate, and the concentration values listed are the result 








Cell Type / Sample Concentration (ug/ml) 
MB231 NORMAL SET 1                                                                       0.61206
MB231 NORMAL SET 2                                                                       0.57072
MB468 NORMAL SET 1                                                                       0.14727
MB468 NORMAL SET 2                                                                       0.38460
MCF7   NORMAL SET 1                                                                        2.54176 
MCF7   NORMAL SET 2                                                                        0.79815 
MB231 HEAT SET 1                                                                              2.71130
MB231 HEAT SET 2   1.73797 
MB468 HEAT SET 1                                                                              1.44132
MB468 HEAT SET 2                                                                              1.84277
MCF7   HEAT SET 1                                                                               4.19536
MCF7   HEAT SET 2                                                                               1.92925
MB231 HYPOXIA SET 1                                                                        0.79297 
MB231 HYPOXIA SET 2                                                                        3.42333 
MB468 HYPOXIA SET 1                                                                        0.23664 
MB468 HYPOXIA SET 2                                                                        0.18551 
MCF7 HYPOXIA SET 1                                                                           6.93616
MCF7 HYPOXIA SET 2                                                                           4.79523
MB231 DUAL STRESS SET 1                                                                 0.95592
MB231 DUAL STRESS SET 2                                                                 2.89751
MB468 DUAL STRESS SET 1                                                                 0.25829
MB468 DUAL STRESS SET 2                                                                 0.44185
MCF7 DUAL STRESS SET 1                                                                    6.68212 
























Kruskal-Wallis analysis of quantified miRNA sample concentrations 
compared for MCF7 breast cancer cells under different stress conditions 
 
The Kruskal-Wallis analysis for MCF7 breast cancer cells reflects a statistically significant 
difference (p < 0.05) in median miRNA concentrations for comparison of cells under normal, 
heat stress, hypoxic stress, and dual stress conditions following quantification 
















Kruskal-Wallis analysis of quantified miRNA sample concentrations 
compared for MB468 breast cancer cells under different stress conditions.  
 
The Kruskal-Wallis analysis for MB468 breast cancer cells reflects a statistically significant 
difference (p < 0.01) in median miRNA concentrations for comparison of cells under normal, 
heat stress, hypoxic stress, and dual stress conditions following quantification, 





















Kruskal-Wallis analysis of quantified miRNA sample concentrations 
compared for MB231 breast cancer cells under different stress conditions.  
 
The Kruskal-Wallis analysis for MB231 breast cancer cells reflects a statistically significant 
difference (p < 0.05) in median miRNA concentrations for comparison of cells under normal, 
heat stress, hypoxic stress, and dual stress conditions following quantification, 
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